ObsEva Announces Dismissal of Moratorium Proceedings
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – December 19, 2022 –...
Pharmaceutical
MediWound Announces Positive Results in U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
MW005 shown to be safe and well-tolerated Data provides clinical efficacy proof-of-concept based on complete clearance of target lesions YAVNE,...
Invivyd Presented Joint Industry Rationale on Potential Expedited Development Pathways for Monoclonal Antibodies at FDA-EMA Workshop
WALTHAM, Mass., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to...
Madrigal Announces Positive Topline Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH and Liver Fibrosis
In MAESTRO-NASH, a 52-week serial liver biopsy Phase 3 study in more than 950 patients, resmetirom achieved both primary endpoints...
XORTX Announces Completion of Dosing in XRX-OXY-101 Clinical Study
CALGARY, Alberta, Dec. 19, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX...
LIfT BioSciences investors increase investment in LIfT and Johnson and Johnson welcomes LIfT into JLABS
LIfT BioSciences investors increase investment in LIfT and Johnson and Johnson welcomes LIfT into JLABS Additional investment supports plans for...
atai Life Sciences Initiates Phase 2b proof-of-concept trial of RL-007 for Cognitive Impairment Associated with Schizophrenia
The phase 2b proof-of-concept trial will evaluate the novel compound, RL-007, for pro-cognitive effects in patients with Cognitive Impairment Associated...
Taysha Gene Therapies Announces Executive Leadership Changes
Chair of the Board of Directors, Sean P. Nolan, appointed Chief Executive Officer Board Director, Sukumar Nagendran, M.D., appointed President...
Wesana Health Announces Receipt of Short-Term Loan
CHICAGO and TORONTO, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF),...
91% of IT and security leaders agree they can no longer rely solely on perimeter security, new Imprivata study finds
The exponential growth of attack surfaces has led many to prioritize security beyond the firewallWALTHAM, Mass., Dec. 15, 2022 (GLOBE...
Management change
ANNOUNCEMENT NO. 233 14 December 2022 Management change Steen Søndergaard has announced that he wants to resign from his position...
Panbela Receives Positive EMA Opinion on Orphan Designation for Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
MINNEAPOLIS, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the...
Israeli Based Biotech Company Clearmind Completes IND-Enabling Studies for CMND-100
The MEAI-based proprietary compound is aimed at treating Alcohol Use Disorder Tel Aviv, Israel / Vancouver, Canada, Dec. 13, 2022...
Quanta Therapeutics Appoints Leonardo Faoro, MD, as Chief Medical Officer
– US board-certified medical oncologist with extensive global clinical and regulatory experience advancing oncology medicines from early development stages through...
SELLAS Announces Positive Phase 1 Data with CDK9 Inhibitor GFH009 Monotherapy in Patients with Relapsed/Refractory Hematologic Malignancies
GFH009 is First CDK9 Inhibitor Monotherapy to Achieve Compete Response in Acute Myeloid Leukemia Anticancer Effects Observed Across Multiple Dose...
Modifi Bio Announces Scientific Advisory Board
SAB brings extensive expertise in precision oncology, drug development, and early phase clinical trialsNEW HAVEN, Conn., Dec. 13, 2022 (GLOBE...
Distinguished Innovator in Genomics Joins the Scientific Advisory Board of Predictive Oncology
Marc Malandro POAI Scientific Advisory BoardEAGAN, Minn., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) today announced the...
Quoin Pharmaceuticals Announces Dosing of First Patient in Clinical Trial in Netherton Syndrome
Company’s Second Netherton Syndrome Clinical Study has been Cleared by FDA to Initiate Testing All Six Target Clinical Sites are...
vTv Therapeutics Appoints Biotech Industry Veteran Steven Tuch as Chief Financial Officer
Steven Tuch, Chief Financial Officer Steven Tuch, Chief Financial Officer Steven Tuch, Chief Financial Officer HIGH POINT, N.C., Dec. 13,...
Investigators Present Clinical Data on Salarius Pharmaceuticals’ Seclidemstat in Patients with MDS and CMML at the 2022 American Society of Hematology Annual Meeting
Patients treated in dose-escalation portion of Phase 1/2 study evaluating seclidemstat in combination with azacitidine 50% overall response rate among...